Consistently, inhibition of PERK/eIF2α signaling enhances chemotherapeutic responses by promoting apoptosis in small-cell lung cancer [37] and chronic myeloid leukemia models [38]. This evidence concerns the gene EIF2A and chronic myelogenous leukemia, BCR-ABL1 positive.